Zanubrutinib Approved for Relapsed/Refractory Marginal Zone Lymphoma

The FDA has granted accelerated approval to zanubrutinib (Brukinsa®, BeiGene) for the treatment of patients with relapsed/refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. "Marginal zone lymphoma is rare and heterogeneous, and it has been difficult to define optimal therapeutic strategies," wrote Stephen Opat, FRACP, FRCPA, MBBS, Director of Clinical Hematology at Monash Health in Australia, and colleagues, in their publication of the initial results...
Continue reading

Recent Advances in T-Cell Lymphoma: A Video Interview With Dr. Steven Horwitz

In this interview, Steven Horwitz, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, speaks with Oncology Data Advisor about the recent advancements in the treatment of T-cell lymphoma. Keira Smith: Hi, I'm Keira Smith from Oncology Data AdvisorTM. I'm here today with Dr. Steven Horwitz. Steven Horwitz, MD: Hi, pleasure to be here. I'm Dr. Steven Horwitz. I'm a medical oncologist at Memorial Sloan Kettering Cancer Center. Keira Smith: What do you consider some of the ...
Continue reading

IPH4102: Potential Treatment for Cutaneous T-Cell Lymphoma

Researchers report that IPH4102, a first-in-class monoclonal antibody that targets killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2), shows promising activity in relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare cancer that affects the skin. A cell surface protein, KIR3DL2 is expressed particularly strongly in patients with a form of CTCL called Sézary syndrome, which is an aggressive blood cancer. This international, first-in-human, open-label phase 1 clinical trial (NCT0259...
Continue reading

CAR T-Cell Therapy: New Treatment for Large B-Cell Lymphoma

Large B-cell lymphoma is an extremely destructive, invasive subtype of non-Hodgkin lymphoma. Often, patients with this malignancy have undergone several treatments that have not worked. New therapeutic approaches are necessary for relapsed/refractory disease. A breakthrough personalized treatment, CAR T-cell therapy may be an option for patients with relapsed/refractory large B-cell lymphoma. Patients undergo a process called leukapheresis, in which a patient's blood is collected and put through...
Continue reading

Brentuximab Vedotin Approved in Peripheral T-Cell Lymphomas

The FDA has expanded the approval of brentuximab vedotin (Adcetris®, Seattle Genetics, Inc.) in combination with chemotherapy as a first-line treatment for adults with systemic anaplastic large cell lymphoma (ALCL) and other peripheral T-cell lymphomas (PTCLs) expressing the tumor marker CD30. This is the first FDA-approved treatment for patients with newly diagnosed PTCLs. Peripheral T-cell lymphomas are a diverse group of rare non-Hodgkin lymphomas that result when the immune system's T cells ...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.